longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Eupraxia Pharmaceuticals

EPRX

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • EPIRUS Therapeutics: Buy Rating Reiterated on EP-104GI’s Emerging Clinical Profile and Upcoming Phase 2b Catalyst; $16 Price Target Unchanged

    Tip Ranks·2 hours ago
    EPRX+9.57%
  • Eupraxia says EP-104GI keeps 64% of EoE patients in remission at 52 weeks in RESOLVE trial data

    PUBT·8 hours ago
    EPRX+9.57%
  • Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated at Wedbush

    Market Beat·Sep 24 at 12:42 PM
    EPRX+9.57%
  • Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Gap Down - Here's What Happened

    Market Beat·Sep 15 at 05:00 PM
    EPRX+9.57%
  • Eupraxia Pharmaceuticals begins trading on Nasdaq Global Select Market after uplisting from Nasdaq Capital Market

    PUBT·Sep 8 at 12:05 PM
    EPRX+9.57%
  • Eupraxia Pharmaceuticals (NASDAQ:EPRX) Sees Strong Trading Volume - Here's Why

    Market Beat·Sep 4 at 06:40 PM
    - Eupraxia Pharmaceuticals experienced a significant surge in trading volume, with 3,055,170 shares traded, representing a 996% increase from the previous session. - The company's stock last traded at $8.01, reflecting a 6.7% increase alongside recent analyst rating adjustments and a market capitalization of $520.49 million. - Several major institutional investors, including the Royal Bank of Canada and JPMorgan Chase & Co., recently adjusted their holdings in the company.
    EPRX+9.57%BAC-0.96%
  • 6 Biotech Stocks To Watch Ahead Of Key Catalysts: RenovoRx, Eupraxia, Connect Bio, Kardigan & More

    rttnews·Sep 3 at 03:23 AM
    EPRX+9.57%RNXT-0.64%
  • Eupraxia posts corporate presentation detailing RESOLVE trial symptom response data

    PUBT·Aug 13 at 12:01 PM
    EPRX+9.57%
  • Eupraxia Therapeutics: Buy Rating Reaffirmed on Advancing EoE Program and RESOLVE Phase 2b Readout, Price Target Maintained at $16

    Tip Ranks·Aug 12 at 06:55 PM
    EPRX+9.57%
  • Cantor Fitzgerald Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)

    Tip Ranks·Aug 12 at 03:05 PM
    EPRX+9.57%
  • Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results | EPRX Stock News

    StockTitan·Aug 11 at 01:21 PM
    EPRX+9.57%